Corrigendum to “Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables” [Int. J. Mycobacteriol. 5(1) 2016 1-6]. Go to Publication You Might Also Like The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. March 15, 2017 COVID-19 care in India: the course to self-reliance September 3, 2020 Clofazimine: an old drug for never-ending diseases September 3, 2020 Interstitial Lung Disease in India. Keep Searching and You’ll Keep Finding. March 15, 2017 Drug-resistant tuberculosis in India. November 6, 2002
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. March 15, 2017